Bristol-Myers Squibb Company (BMY) trades at a trailing P/E of 17.1, forward P/E of 9.3. Trailing earnings yield is 5.85%, forward earnings yield 10.80%. PEG 0.11 (Peter Lynch undervalued ≤1.0). Graham Number is $26.55.
Criteria proven by this page:
Overall SharesGrow Score: 56/100 with 2/7 criteria passed.
| Year | P/E (TTM) | PEG Ratio | P/B Ratio | P/S Ratio | Dividend Yield |
|---|---|---|---|---|---|
| 2016 | 21.9 | 0.13 | 6.04 | 5.03 | 2.61% |
| 2017 | 100.1 | -1.30 | 8.59 | 4.85 | 2.56% |
| 2018 | 17.3 | 0.04 | 6.05 | 3.76 | 3.08% |
| 2019 | 31.8 | -0.95 | 2.12 | 4.19 | 2.45% |
| 2020 | -15.6 | 0.05 | 3.70 | 3.29 | 2.91% |
| 2021 | 19.8 | -0.11 | 3.85 | 2.99 | 3.17% |
| 2022 | 24.2 | -4.24 | 4.93 | 3.32 | 3.02% |
| 2023 | 13.2 | 0.43 | 3.61 | 2.36 | 4.47% |
| 2024 | -12.8 | 0.06 | 7.02 | 2.37 | 4.24% |
| 2025 | 15.6 | -0.09 | 5.96 | 2.28 | 4.58% |
| Year | EPS (Diluted) | Revenue | Net Income | Net Margin |
|---|---|---|---|---|
| 2016 | $2.65 | $19.43B | $4.46B | 22.9% |
| 2017 | $0.61 | $20.78B | $1.01B | 4.8% |
| 2018 | $3.03 | $22.56B | $4.95B | 21.9% |
| 2019 | $2.01 | $26.15B | $3.44B | 13.2% |
| 2020 | $-3.98 | $42.52B | $-9B | -21.2% |
| 2021 | $3.12 | $46.39B | $6.99B | 15.1% |
| 2022 | $2.95 | $46.16B | $6.33B | 13.7% |
| 2023 | $3.86 | $45.01B | $8.03B | 17.8% |
| 2024 | $-4.41 | $48.3B | $-8.95B | -18.5% |
| 2025 | $3.45 | $48.19B | $7.05B | 14.6% |
| Year | EPS (Avg) | EPS Range | Revenue (Avg) | Revenue Range | Analysts |
|---|---|---|---|---|---|
| 2026 | $6.26 | $6.02 – $6.35 | $46.89B | $46.45B – $47.14B | 17 |
| 2027 | $6.13 | $5.46 – $6.82 | $45.97B | $44.94B – $47.36B | 16 |
| 2028 | $5.45 | $3.95 – $6.45 | $40.75B | $40.72B – $40.77B | 10 |
| 2029 | $4.91 | $4.67 – $5.03 | $37.07B | $35.68B – $37.77B | 4 |
| 2030 | $4.89 | $4.65 – $5.01 | $36.42B | $35.06B – $37.11B | 4 |
